Elypta
Molecular diagnostic company focused on preventing cancer mortality by developing a metabolism-based liquid biopsy platform for early detection and monitoring of the disease.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD130—195m (Dealroom.co estimates Jun 2022.)
Company register number 559112-1214
Solna kommun Stockholm County (HQ)
- hard tech
- biotechnology
- horizon europe
- sustainable development goals
- eit ecosystem
- oncology
- eit health
- nordic rising star 2022
- techbio
- ai drug discovery
- digital pharma
- techbio drug discovery
- medical diagnostics
- metabolism
- mentoring and coaching network (eit health)
- biomarkers
- mentoring and coaching network 2019 (eit health)
- digital sandbox (eit health)
- digital sandbox 2019 (eit health)
Financials
Estimates*
| EUR | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Revenues | <1m | <1m | <1m | <1m | <1m |
| % growth | - | 5 % | (71 %) | 1336 % | (66 %) |
| EBITDA | - | (<1m) | (<1m) | (1.3m) | (2.7m) |
| % EBITDA margin | - | (1862 %) | (8829 %) | (1042 %) | (6615 %) |
| Profit | (<1m) | (<1m) | (<1m) | (1.3m) | (2.8m) |
| % profit margin | (488 %) | (1876 %) | (9255 %) | (1094 %) | (6839 %) |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | SEK3.0m | Seed | |
SEK15.5m | Seed | ||
€2.3m | Grant | ||
€30.0k | Grant | ||
SEK65.0m | Seed | ||
* | $21.0m | Series A | |
N/A | Support Program | ||
* | $1.0m | Grant | |
| Total Funding | AUD53.6m | ||
Related Content
Recent News about Elypta
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.